| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |